CAR-T Toxicities Consortium
The Chimeric Antigen Receptor T-Cell Therapies Toxicities Consortium unites investigators in scientific and medical associations, government agencies, and registries, to address emerging CAR-T-related toxicities as T-cell therapies continue to be used, as a treatment approach for hematologic malignancies.
Goals and Objectives
The consortium, consisting of representatives from scientific and medical associations, U.S. Food and Drug Administration (FDA) and the Center for International Blood and Marrow Transplant Research (CIBMTR) working together, is meant to address urgent needs related to emerging CAR-T adverse events and identify opportunities to address the following areas:
- Increasing investigators’ understanding of the molecular mechanisms surrounding these toxicities and the role conditioning regimens could play in their onset.
- Exploring ways to effectively report and catalog these toxicities to inform future research.
- Developing educational resources for clinicians to inform toxicity management approaches.
- Informing regulatory agencies on the challenges and recent developments in the field surrounding this topic.
Current Focus
The consortium is expected to convene on a bi-monthly basis (i.e., every other month) with its first order of business being to conduct a landscape analysis of the field and that based on its assessment, it will then ascertain and develop resources to address important gaps.
Consortium Members
The consortium consists of individuals who have expertise in CAR-T cells and the ability to carry forward recommendations from this consortium to their respective organizations.
American Society of Hematology
Nirali N. Shah, MD, MHSc, (Chair)
Robert S Negrin, MD, PhD, (Vice Chair)
Alice Kuaban, MS, (Staff Liason)
ASH Research Collaborative
Saad Usmani, MD, MBA, FACP, FASCO, (Chair)
William Wood, MD, MPH, (Vice Chair)
Food and Drug Administration
Nicole Verdun, MD, (Chair)
American Association for Cancer Research
Helen E. Heslop, MD, DSc (Hon), (Chair)
Nikhil C. Munshi, MD, (Vice Chair)
Maximilian F. Konig, MD, DSc (Hon), (Chair)
C. Thomas Appleton, MD, PhD, FRCPC, (Vice Chair)
American Society for Transplantation and Cellular Therapies
Frederick Locke, MD, (Chair)
Marcela Maus, MD, PhD, (Vice Chair)
Center for International Blood and Marrow Transplant Research
Marcelo Pasquini, MD, MS, (Chair)
American Society of Gene and Cell Therapies
Isabelle Riviere, PhD, (Chair)
Marco Davila, MD, PhD, (Vice Chair)
International Society for Cell and Gene Therapy
Bruce Levine, PhD, (Chair)
Jaap Jan Boelens, MD, PhD, (Vice Chair)
Society for Immunotherapy of
Cancer
Kristen Hege, MD, (Chair)
Sarah Warren, PhD, (Vice Chair)
Questions?
For more information on the Cart-T Toxicities Consortium, please contact ASH’s Director of Scientific Affairs, Alice Kuaban, MS at [email protected].
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission